Publication Name	World Journal of Clinical Cases
Manuscript ID	13708
Country

Received	2014-08-29 08:32
Peer-Review Started	2014-08-29 17:40
To Make the First Decision	2014-10-14 18:03
Return for Revision	2014-10-20 16:43
Revised	2014-11-01 20:22
Second Decision	2014-12-23 20:11
Accepted by Journal Editor-in-Chief	2014-12-23 20:50
Accepted by Executive Editor-in-Chief	2014-12-31 13:43
Articles in Press	2014-12-31 13:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-02-27 16:54
Publish the Manuscript Online	2015-03-13 15:29

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6
Manuscript Source	Invited Manuscript
All Author List	Vasilios Papastergiou and Stylianos Karatapanis
Funding Agency and Grant Number
Corresponding Author	Dr. Vasilios Papastergiou, Department of Internal Medicine, General Hospital of Rhodes, 49 Peiraios Str, 85100 Rhodes, Greece. vasi.pap@hotmail.com
Key Words	Hepatitis C virus; Genotype 4; Genotype 5; Genotype 6; Pegylated interferon; Ribavirin; Direct-acting antivirals
Core Tip	Hepatitis C virus (HCV) 4, 5 and 6 are lesser known genotypes mainly encountered in Africa, the Middle East and Asia. Studies, mostly retrospective, have reported response rates to a 48-wk peginterferon/ribavirin combination ranging to 40%-69% for HCV-4, 55%-60% for HCV-5 and 60%-90% for HCV-6. Increasing evidence has supported a response-guided approach for HCV-4, whereas no robust data are yet available concerning tailoring of treatment duration for HCV-5 and HCV-6. Direct-acting antivirals may significantly improve treatment outcomes in HCV, but use of these agents in countries endemic for HCV 4-6 is currently precluded by the very high costs.
Publish Date	2015-03-13 15:29
Citation	Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3(3): 210-220
URL	http://www.wjgnet.com/2307-8960/full/v3/i3/210.htm
DOI	http://dx.doi.org/10.12998/wjcc.v3.i3.210

Full Article (PDF)	WJCC-3-210.pdf
Full Article (Word)	WJCC-3-210.doc
Manuscript File	13708-Review.docx
Answering Reviewers	13708-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13708-Conflict-of-interest statement.pdf
Copyright License Agreement	13708-Copyright assignment.pdf
Peer-review Report	13708-Peer review(s).pdf
Scientific Misconduct Check	13708-CrossCheck.jpg
Scientific Editor Work List	13708-Scientific editor work list.pdf